Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

The goal of this clinical trial is to learn if veverimer will reduce urinary net acidexcretion leading to reduced bone resorption in healthy adults with osteopenia. The mainquestions it aims to answer are: ‐ How much does each dose of veverimer (vs. placebo) reduce 24‐hr urinary net acidexcretion. ‐ Describe the safety of veverimer based on changes in serum bicarbonate andpotassium. ‐ Assess the changes in bone resorption. ‐ Assess the changes in bone formation. ‐ Explore the effect of veverimer on physical performance.Participants will: ‐ Take veverimer or placebo every day or every other day for 8 weeks ‐ Visit the clinic a total of 8 times (including screening) for checkups and testing ‐ Keep a medication diary tracking each day they take the study drug